{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:29:09Z","timestamp":1792787349872,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007824","name":"Soochow University","doi-asserted-by":"publisher","award":["H240075"],"award-info":[{"award-number":["H240075"]}],"id":[{"id":"10.13039\/501100007824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018556","name":"Science and Technology Program of Suzhou","doi-asserted-by":"publisher","award":["SYW2024001"],"award-info":[{"award-number":["SYW2024001"]}],"id":[{"id":"10.13039\/501100018556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018556","name":"Science and Technology Program of Suzhou","doi-asserted-by":"publisher","award":["2021ZCMS08"],"award-info":[{"award-number":["2021ZCMS08"]}],"id":[{"id":"10.13039\/501100018556","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.drudis.2025.104549","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:29:54Z","timestamp":1763641794000},"page":"104549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mechanisms and interventions in relapsed\/refractory extranodal natural killer\/T-cell lymphoma"],"prefix":"10.1016","volume":"30","author":[{"given":"Qisi","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-097X","authenticated-orcid":false,"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104549_b0005","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.clml.2017.10.001","article-title":"Management of advanced and relapsed\/refractory extranodal natural killer T-cell lymphoma: an analysis of stem cell transplantation and chemotherapy outcomes","volume":"18","author":"Brammer","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.drudis.2025.104549_b0010","article-title":"How oncovirus affects drug resistance in cancer cells","author":"Yang","year":"2025","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"10.1016\/j.drudis.2025.104549_b0015","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00277-018-3313-x","article-title":"Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma","volume":"97","author":"Cho","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.drudis.2025.104549_b0020","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ccell.2020.02.005","article-title":"Genomic and transcriptomic characterization of natural killer T cell lymphoma","volume":"37","author":"Xiong","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2025.104549_b0025","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.pathol.2022.12.350","article-title":"An update on genetic aberrations in T-cell neoplasms","volume":"55","author":"Parilla","year":"2023","journal-title":"Pathology"},{"key":"10.1016\/j.drudis.2025.104549_b0030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000500974","article-title":"Programmed cell death 1 and programmed cell death ligands in extranodal natural killer\/T cell lymphoma: expression pattern and potential prognostic relevance","volume":"143","author":"Muhamad","year":"2020","journal-title":"Acta Haematol"},{"key":"10.1016\/j.drudis.2025.104549_b0035","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s00277-023-05605-8","article-title":"Immunotyping of peripheral blood lymphocytes by flow cytometry reveals Th cell as a potential prognostic biomarker for extranodal NK\/T-cell lymphoma","volume":"103","author":"Qi","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.drudis.2025.104549_b0040","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41379-019-0392-8","article-title":"Immune subtyping of extranodal NK\/T-cell lymphoma: a new biomarker and an immune shift during disease progression","volume":"33","author":"Cho","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.drudis.2025.104549_b0045","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1007\/s12032-012-0244-6","article-title":"High numbers of tumor-associated macrophages correlate with poor prognosis in patients with mature T- and natural killer cell lymphomas","volume":"29","author":"Lin","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.drudis.2025.104549_b0050","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.3390\/cancers12123548","article-title":"Serum-derived exosomal MicroRNA profiles can predict poor survival outcomes in patients with extranodal natural killer\/T-cell lymphoma","volume":"12","author":"Ryu","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104549_b0055","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1515\/med-2021-0409","article-title":"The biomarkers of key miRNAs and gene targets associated with extranodal NK\/T-cell lymphoma","volume":"17","author":"Peng","year":"2022","journal-title":"Open Med"},{"key":"10.1016\/j.drudis.2025.104549_b0060","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00277-023-05579-7","article-title":"Elevated serum IL-6 and total IgEAb are associated with poor survival in natural killer\/T-cell lymphoma","volume":"103","author":"Hui","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.drudis.2025.104549_b0065","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/10428194.2018.1480772","article-title":"Serum IL18 is associated with hemophagocytosis and poor survival in extranodal natural killer\/T-cell lymphoma","volume":"60","author":"Lim","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.drudis.2025.104549_b0070","doi-asserted-by":"crossref","first-page":"150","DOI":"10.14715\/cmb\/2023.69.3.22","article-title":"Diagnostic value of IL-22, IL-23, and IL-17 for NK\/T cell lymphoma","volume":"69","author":"Qi","year":"2023","journal-title":"Cell Mol Biol"},{"key":"10.1016\/j.drudis.2025.104549_b0075","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.cyto.2016.09.011","article-title":"Serum B-cell activating factor predicts prognosis in nasal type, extranodal NK\/T cell lymphoma","volume":"88","author":"Zhang","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.drudis.2025.104549_b0080","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00262-023-03394-7","article-title":"Expression of soluble CD27 in extranodal natural killer\/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27\/CD70-targeted therapy","volume":"72","author":"Nagato","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.drudis.2025.104549_b0085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12943-021-01374-y","article-title":"GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer\/T cell lymphoma","volume":"20","author":"Rong","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.drudis.2025.104549_b0090","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-015-0142-4","article-title":"The serum CXCL13 level is associated with the Glasgow prognostic score in extranodal NK\/T-cell lymphoma patients","volume":"8","author":"Kim","year":"2015","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2025.104549_b0095","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00262-015-1675-7","article-title":"CCL17 and CCL22\/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer\/T-cell lymphoma","volume":"64","author":"Kumai","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.drudis.2025.104549_b0100","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hon.2283","article-title":"Macrophage inflammatory protein 1 alpha (MIP-1\u03b1) may be associated with poor outcome in patients with extranodal NK\/T-cell lymphoma","volume":"35","author":"Kim","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.drudis.2025.104549_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0609.2007.00876.x","article-title":"Prognostic factors for classifying extranodal NK\/T cell lymphoma, nasal type, as lymphoid neoplasia","volume":"79","author":"Na","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.drudis.2025.104549_b0110","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/annonc\/mdq314","article-title":"Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer\/T-cell lymphoma, nasal type","volume":"22","author":"Huang","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2025.104549_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100905","article-title":"ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance","volume":"66","author":"Fan","year":"2023","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drudis.2025.104549_b0120","first-page":"1359","article-title":"Down-regulation of intracellular reactive oxygen species attenuates P-glycoprotein-associated chemoresistance in Epstein-Barr virus-positive NK\/T-cell lymphoma","volume":"11","author":"Nam","year":"2019","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.drudis.2025.104549_b0125","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.leukres.2015.10.001","article-title":"ATP-binding cassette sub-family C member 4 (ABCC4) is overexpressed in human NK\/T-cell lymphoma and regulates chemotherapy sensitivity: potential as a functional therapeutic target","volume":"39","author":"Zhang","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.drudis.2025.104549_b0130","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/iub.2410","article-title":"m6A methyltransferase Wilms\u2019 tumor 1-associated protein facilitates cell proliferation and cisplatin resistance in NK\/T cell lymphoma by regulating dual-specificity phosphatases 6 expression via m6A RNA methylation","volume":"73","author":"Ma","year":"2021","journal-title":"IUBMB Life"},{"key":"10.1016\/j.drudis.2025.104549_b0135","doi-asserted-by":"crossref","first-page":"12628","DOI":"10.1002\/jcb.28529","article-title":"c-Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer\/T-cell lymphoma","volume":"120","author":"Zhu","year":"2019","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.drudis.2025.104549_b0140","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1158\/1078-0432.CCR-14-1216","article-title":"Global promoter methylation analysis reveals novel candidate tumor suppressor genes in natural killer cell lymphoma","volume":"21","author":"K\u00fc\u00e7\u00fck","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104549_b0145","doi-asserted-by":"crossref","first-page":"8068","DOI":"10.1038\/srep08068","article-title":"Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines","volume":"5","author":"Chien","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104549_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100907","article-title":"Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade","volume":"66","author":"Pang","year":"2023","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drudis.2025.104549_b0155","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1038\/s41375-020-1000-0","article-title":"Whole-genome sequencing identifies responders to Pembrolizumab in relapse\/refractory natural-killer\/T cell lymphoma","volume":"34","author":"Lim","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2025.104549_b0160","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00277-015-2359-2","article-title":"CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK\/T cell lymphoma, nasal type","volume":"94","author":"Wang","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.drudis.2025.104549_b0165","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104549_b0170","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00228-024-03711-8","article-title":"Population pharmacokinetics of free and liposome-encapsulated mitoxantrone in patients with relapsed\/refractory lymphoma or small cell lung cancer","volume":"80","author":"Xu","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"issue":"suppl. 1","key":"10.1016\/j.drudis.2025.104549_b0175","first-page":"36","article-title":"Safety and efficacy of mitoxantrone hydrochloride liposome in patients with relapsed or refractory peripheral T-cell lymphoma and extranodal NK\/T-cell lymphoma: a prospective, single-arm, open-label, multi-center, phase \u2161 clinical trial","volume":"136","author":"Gao","year":"2020","journal-title":"Blood"},{"issue":"suppl. 1","key":"10.1016\/j.drudis.2025.104549_b0180","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1182\/blood-2022-163343","article-title":"Combination of mitoxantrone hydrochloride liposome with cyclophosphamide, vincristine and prednisone (CMOP) in treatment-na\u00efve patients with peripheral T-cell lymphoma: a multicenter, open-label, single-arm, phase Ib clinical trial","volume":"140","author":"Huang","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2025.104549_b0185","article-title":"Efficacy and safety analysis of combination therapy based on mitoxantrone hydrochloride liposome injection (Lipo-MIT) in relapsed\/refractory NK\/T-cell lymphoma","volume":"14","author":"Wang","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2025.104549_b0190","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2020007247","article-title":"Avelumab for the treatment of relapsed or refractory extranodal NK\/T-cell lymphoma: an open-label phase 2 study","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2025.104549_b0195","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.22.02367","article-title":"Sugemalimab monotherapy for patients with relapsed or refractory extranodal natural killer\/T-cell lymphoma (GEMSTONE-201): results from a single-arm, multicenter phase II study","volume":"41","author":"Huang","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104549_b0200","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2025.104549_b0205","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","article-title":"Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)","volume":"14","author":"Shi","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2025.104549_b0210","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41392-024-01825-0","article-title":"Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib\/II study","volume":"9","author":"Gao","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2025.104549_b0215","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1007\/s00277-024-05739-3","article-title":"Optimization of immune checkpoint inhibitor treatment planning for relapsed or refractory extranodal NK\/T cell lymphoma","volume":"103","author":"Yoon","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.drudis.2025.104549_b0220","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdv596","article-title":"Epstein-Barr virus reactivation in extranodal natural killer\/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin","volume":"27","author":"Kim","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2025.104549_b0225","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/annonc\/mdw231","article-title":"Histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer\/T-cell lymphoma (ENKTL)","volume":"27","author":"Tan","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2025.104549_b0230","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"suppl. 1","key":"10.1016\/j.drudis.2025.104549_b0235","doi-asserted-by":"crossref","first-page":"9393","DOI":"10.1182\/blood-2022-165874","article-title":"DNA-demethylating agents combined with anti-PD-1 inhibitors showed activity in patients with relapsed or refractory extranodal NK\/T cell lymphoma who have failed immunotherapy: an exploratory study","volume":"140","author":"Yan","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2025.104549_b0240","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4143\/crt.2019.198","article-title":"Efficacy of brentuximab vedotin in relapsed or refractory high-CD30-expressing non-hodgkin lymphomas: results of a multicenter, open-labeled phase II trial","volume":"52","author":"Kim","year":"2020","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.drudis.2025.104549_b0245","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3324\/haematol.2021.278301","article-title":"A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas","volume":"106","author":"Kim","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.drudis.2025.104549_b0250","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","article-title":"CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin","volume":"14","author":"Chen","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2025.104549_b0255","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00277-015-2359-2","article-title":"CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK\/T cell lymphoma, nasal type","volume":"94","author":"Wang","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.drudis.2025.104549_b0260","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-020-01020-y","article-title":"Daratumumab monotherapy for patients with relapsed or refractory natural killer\/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study","volume":"14","author":"Huang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2025.104549_b0265","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/hon.3089","article-title":"A phase 1\/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma","volume":"41","author":"Carlo-Stella","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.drudis.2025.104549_b0270","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.3390\/cancers14174169","article-title":"Targeting CD38 in neoplasms and non-cancer diseases","volume":"14","author":"Szlasa","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104549_b0275","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40880-018-0334-8","article-title":"IL-2R\u03b1 up-regulation is mediated by latent membrane protein 1 and promotes lymphomagenesis and chemotherapy resistance in natural killer\/T-cell lymphoma","volume":"38","author":"Wang","year":"2018","journal-title":"Cancer Commun"},{"key":"10.1016\/j.drudis.2025.104549_b0280","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-2141.2008.07000.x","article-title":"Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer\/T cell malignancy","volume":"141","author":"Ishitsuka","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.drudis.2025.104549_b0285","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1086\/466530","article-title":"Coexpression of CD40 and CD40 ligand in Epstein-Barr virus-infected T and NK cells and their role in cell survival","volume":"192","author":"Imadome","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.drudis.2025.104549_b0290","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"JCO"},{"key":"10.1016\/j.drudis.2025.104549_b0295","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s00277-021-04558-0","article-title":"Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK\/T lymphoma: results of a multicenter study","volume":"100","author":"Kim","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.drudis.2025.104549_b0300","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1172\/JCI32103","article-title":"Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates","volume":"118","author":"Berger","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2025.104549_b0305","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/2159-8290.CD-12-0028","article-title":"Janus kinase 3-activating mutations identified in natural killer\/T-cell lymphoma","volume":"2","author":"Koo","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2025.104549_b0310","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s40265-024-02089-2","article-title":"Golidocitinib: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2025.104549_b0315","first-page":"7034","article-title":"Selection of new immunotherapy targets for NK\/T cell lymphoma","volume":"12","author":"Lv","year":"2020","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.drudis.2025.104549_b0320","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1093\/annonc\/mdn431","article-title":"Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK\/T-cell lymphoma","volume":"19","author":"Lee","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2025.104549_b0325","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.1182\/blood.V128.22.5353.5353","article-title":"A phase II study of bortezomib-GIFOX (gemcitabine, ifosfamide, oxaliplatin) in patients with newly diagnosed natural-killer\/T-cell lymphoma","volume":"128","author":"Tang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2025.104549_b0330","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3892\/mco.2017.1364","article-title":"Treatment of relapsed extranodal natural killer\/T-cell lymphoma with bortezomib plus fludarabine","volume":"7","author":"Chen","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104549_b0335","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1158\/1078-0432.CCR-13-3172","article-title":"mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells","volume":"20","author":"Kawada","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104549_b0340","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bjh.16435","article-title":"Evaluation of the PIK3 pathway in peripheral T\u2010cell lymphoma and NK\/T\u2010cell lymphoma","volume":"189","author":"Huang","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.drudis.2025.104549_b0345","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-023-01483-9","article-title":"Novel target and treatment agents for natural killer\/T-cell lymphoma","volume":"16","author":"Tian","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2025.104549_b0350","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","volume":"23","author":"Kharfan-Dabaja","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.drudis.2025.104549_b0355","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/s41375-023-01924-x","article-title":"Allogeneic hematopoietic stem cell transplantation for NK\/T-cell lymphoma: an international collaborative analysis","volume":"37","author":"Berning","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2025.104549_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100770","article-title":"Efficacy of B7-H3-redirected BiTE and CAR-T immunotherapies against extranodal nasal natural killer\/T cell lymphoma","volume":"13","author":"Zheng","year":"2020","journal-title":"Transl Oncol"},{"key":"10.1016\/j.drudis.2025.104549_b0365","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13046-022-02421-2","article-title":"Expanding anti-CD38 immunotherapy for lymphoid malignancies","volume":"41","author":"Wang","year":"2022","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625002624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625002624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:12:50Z","timestamp":1780920770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625002624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":73,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1359644625002624"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104549","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms and interventions in relapsed\/refractory extranodal natural killer\/T-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104549","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104549"}}